Phaseline

Companies › Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair

Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Metabolic and endocrine, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Saxagliptin Hydrochloride
Dipeptidyl peptidase IV inhibitor
DPP4Phase 2Type 2 DiabetesNov 2026
Topotecan
DNA topoisomerase I inhibitor
TOP1Phase 2SCLCDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07033585Saxagliptin HydrochloridePhase 2Type 2 DiabetesMetabolic and endocrineNov 2026
NCT07145333TopotecanPhase 2SCLCOncologyDec 2026

Targets

DPP4 (1) TOP1 (1)

Companies with the same targets

AstraZeneca Daiichi Sankyo Merck & Co. (MSD) CSPC Ouyi Pharmaceutical Nabiqasim Industries (Pvt) JW Pharmaceutical Gilead Sciences Klus Pharma Fujifilm Pharmaceuticals U.S.A. Targeted Therapy Technologies

Companies built like this

CEBIOTEX Targeted Therapy Technologies CNS Pharmaceuticals Alpheus Medical Nabiqasim Industries (Pvt)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.